ITALCHIMICI, a leader in ethical drugs and dietary supplements, has been acquired by Progressio Investimenti II and IDEA CAPITAL FUNDS, with a focus on leveraging growth in the Italian pharmaceutical market.

Information on the Target

ITALCHIMICI is a prominent company specializing in the marketing of ethical drugs and dietary supplements, particularly for respiratory diseases, gastrointestinal disorders, and pediatric medications. Recently, the company's ownership has transitioned to two investment funds, while the management team retains minority stakes in the organization.

The deal was spearheaded by Riccardo Zagaria, a seasoned manager with an extensive international background at major pharmaceutical firms including Sanofi, Nycomed, and Zambon. Under this new arrangement, the company reported sales of €49 million in 2014 and is poised for further growth with a fresh management team, including Zagaria as the CEO and key members with impressive resumes in the pharmaceutical sector.

Industry Overview in Italy

The Italian pharmaceutical industry is known for its innovation and quality, featuring a robust network of companies that synthesize research and production capabilities. Governed by rigorous regulations, the market focuses on ethical pharmaceutical